What Sustac Treats: Main Uses and Benefits

Sustac is commonly used for the continuous, scheduled management of Stable Angina Pectoris, a chronic condition characterized by generally recurring chest discomfort. As a long-acting nitroglycerin formulation, this type of medication is indicated for the prevention of angina pectoris due to coronary artery disease. The sustained-release formulation is relevant in contexts marked by increased discomfort or tension, specifically for conditions involving episodic or fluctuating manifestations such as stable angina and exertional angina.

The sustained-release formulation is applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load associated with Coronary Artery Disease (CAD). This anti-anginal treatment plays a role in managing symptoms that manifest as Exertional Angina, where chest discomfort is generally triggered by physical activity. The primary therapeutic objective is to assist with maintaining functional stability and supporting tolerance to physical effort, which contributes to easing the symptom load during daily functioning.

“The medication helps maintain a sense of stability and supports patients during episodes of heightened discomfort.”

Quick Fact: Relief for Angina Pectoris
Primary Use Context	Long-term, scheduled prophylactic management.
Symptom Axis	Symptoms related to physical discomfort and exertion.
Patient Benefit Focus	Supports maintaining functional stability and improved tolerance to effort.

Regulatory References

1. NIH DailyMed drug label

Who Can and Cannot Use Sustac? — Official Regulatory Information

The eligibility for using Sustac (Nitroglycerin sustained-release) is strictly defined by regulatory authorities based on population safety and medical conditions.

Absolute Contraindications (Must Not Use)

Sustac is contraindicated for patients with specific health conditions or who are taking certain medications, as stated in official labeling:

• Known hypersensitivity or allergy to Nitroglycerin or other organic nitrates.
• Concurrent use of Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) or Soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat).
• Severe Anemia or conditions leading to Increased Intracranial Pressure (e.g., head trauma).
• Acute Circulatory Failure or Shock.

Population Eligibility Rules

Population Group	Regulatory Status
Adults (18+)	Approved use population.
Pediatric Patients	Safety and effectiveness have not been established.
Pregnancy	Conditional use (Category C). Only if clearly needed.
Severe Hypotension	Caution required (restricted use).

The safety profile is established for adults. Use in pregnant or breastfeeding women is conditional and should only occur if the therapeutic necessity is determined to be essential. Caution is also advised for older adults and individuals with pre-existing severe hypotension.

Sustac Interactions with other medicines and products

This section outlines the officially documented interaction profile for Nitroglycerin (the active ingredient in Sustac), based strictly on government regulatory documents.

Classification	Interacting Medicines and Products	Official Regulatory Statement
Formally Contraindicated	Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil, Avanafil); Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat)	Co-administration is absolutely prohibited due to potentiation of hypotensive effects, risking severe hypotension and cardiovascular collapse. Use within a few days of one another is not recommended.
Pharmacodynamic Additive Effects	Antihypertensive Drugs (e.g., Beta-blockers, Calcium Channel Blockers, Phenothiazines, Tricyclic Antidepressants); Alcohol	Concomitant use may result in additive hypotensive effects. Marked orthostatic hypotension has been reported with calcium channel blockers. Alcohol may also cause hypotension.
Pharmacokinetic/Exposure Alteration	Aspirin (Acetylsalicylic Acid)	Co-administration has been reported to increase Nitroglycerin Cmax and AUC (exposure) by as much as 73%.
Effect Modification	Heparin (Intravenous); Alteplase; Ergotamine/Dihydroergotamine	Intravenous Nitroglycerin reduces the anticoagulant effect of Heparin (requiring mandatory APTT monitoring); Nitroglycerin decreases the thrombolytic effect of Alteplase; Oral administration increases Dihydroergotamine’s oral bioavailability, raising the possibility of ergotism.

The official interaction profile is characterized by mandatory restrictions on agents that cause significant pharmacodynamic potentiation, such as PDE-5 inhibitors. It also defines constraints where Exposure Modification occurs, formally documenting the need for monitoring and adjustments when the effects of agents like Heparin and Alteplase are reduced by Nitroglycerin.

Intracellular Bioactivation and Nitric Oxide Cascade

This section explains how Nitroglycerin is chemically transformed within the cell by the enzyme Mitochondrial Aldehyde Dehydrogenase (ALDH2) to release Nitric Oxide (NO), a signaling molecule. The NO then activates soluble Guanylate Cyclase (sGC), initiating the primary cGMP signaling cascade that controls the vascular muscle tone.

---

Modulating Vascular Smooth Muscle Tone

The rise in cGMP levels triggered by NO leads to the dephosphorylation of proteins, resulting in the physical relaxation of vascular smooth muscle. This smooth muscle relaxation causes systemic vasodilation, or the widening of the blood vessels, which is the resulting physiological consequence of the drug's mechanism.

---

Reducing Cardiac Workload (Preload and Afterload)

The resulting vasodilation preferentially affects the large veins, which expands vascular capacitance. This significantly reduces the volume and pressure of blood returning to the heart (preload). By lowering the cardiac workload and reducing the stretch on the heart muscle, the mechanism directly lowers the heart's oxygen demand.

The administration of Sustac, which contains the active ingredient nitroglycerin, is governed by a cyclic use pattern for the prophylactic management of stable angina pectoris. The established route of administration is oral, utilizing the modified-release tablet or extended-release capsule formulation. These oral sustained-release products are not intended for the treatment of an acute anginal attack due to their intentionally slow onset of action.

Standard adult dosing regimens typically start with lower strengths, ranging from 2.5 mg to 6.5 mg, with maintenance doses scheduled for administration multiple times daily (e.g., two, three, or four times daily). The dosing schedule is structured to incorporate a nitrate-free interval of approximately 10 to 12 hours each day. This specific time-off-drug period is utilized to prevent the development of pharmacological tolerance, which can lead to a reduction in the medication's intended efficacy.

To maintain the controlled-release properties of the medication, the tablets or capsules are intended to be swallowed whole and are not to be crushed, chewed, or divided. For specific populations, such as older adults (geriatric), initial dose selection is typically approach with caution, often beginning at the lowest end of the established range. Furthermore, if long-term treatment is to be discontinued, the dosage is generally gradually reduced over a period of time rather than being abruptly halted.

Research Evidence / Overview of Studies for Sustac

---

Evidence for Stable Angina Pectoris Prophylaxis

The research base for sustained-release nitroglycerin was evaluated in studies exploring the scheduled, long-term management of stable angina pectoris. The evidence primarily comes from short-term, randomized, controlled trials (RCTs), which are standard study designs for evaluating symptom patterns. These studies monitored the measured frequency of patient-reported anginal episodes during the study period. Findings describe patterns observed in these studies regarding the consumption of short-acting, sublingual rescue medication.

What remains uncertain is the full picture of outcomes extending beyond the typical study duration of a few weeks or months. Long-term effects are not fully established regarding the ability to maintain these observed symptom patterns over many years. Also, data for certain groups remain insufficient to fully characterize findings across every possible patient subgroup.

---

Studies on Exertional Angina and Physical Tolerance

Sustained-release nitroglycerin was evaluated in research exploring how symptoms are affected by physical activity. The study designs typically involve Exercise Tolerance Testing (ETT) studies and crossover trials. These studies were applied in patient groups whose angina is reliably triggered by exertion, focusing on functional measures and outcomes reflecting physical effort tolerance.

Research describes the time measured until patients reported the onset of anginal symptoms during standardized testing protocols. Studies monitored measurements of time patients were able to sustain physical effort before discomfort began. These observations were observed in some studies when trial designs included specific measures intended to address the studied issue of nitrate tolerance, a factor that studies explored as potentially limiting the measurements.

---

Key Uncertainties and Research Gaps

One of the main research gaps is related to nitrate tolerance, where studies suggest that a sustained, continuous level of the medicine may lead to a diminished measured effect over time. This requires specific dosing regimens, which research was observed to use in trials to maintain the anti-anginal measurements. Furthermore, comparative evidence is lacking regarding the medicine's long-term effect relative to other currently used anti-anginal treatments.

Key Studies & References

1. Nitroglycerin Extended-Release Capsules - Official DailyMed Drug Label
2. Nitrates and Nitrites for Angina - General Drug Information

Common questions about Sustac (FAQ)

---

Q: Is it approved to treat anxiety?

According to official regulatory documents, Sustac is indicated for several conditions, including the management of neuropathic pain, fibromyalgia, and as an add-on therapy for partial-onset seizures. While some international regulatory documents include generalized anxiety disorder as an indication, the indications for use may vary depending on the regulatory agency and country.

---

Q: Does it cause weight gain?

Yes, weight gain is frequently listed as an adverse reaction in the official product information, according to clinical trials. This is one of the more common side effects associated with the medication.

---

Q: Can I drink alcohol with it?

Official warnings caution against consuming alcohol while using this medication. Combining Sustac with alcohol or other medicines that slow down the central nervous system (CNS depressants) can increase side effects such as dizziness and somnolence (sleepiness).

---

Q: Does it cause breathing problems?

Official safety information includes a warning about the potential for respiratory depression, which refers to serious breathing difficulties. The risk may be increased when combined with other central nervous system (CNS) depressants or in individuals with pre-existing respiratory issues, according to regulatory warnings.

---

Q: Can children 2 years old use it?

The regulatory documents state that Sustac is approved for use in patients as young as 1 month old only as an add-on treatment for partial-onset seizures. For children, official approval is generally restricted to use as an add-on treatment for partial-onset seizures.

---

Q: Does it make you sleepy?

Yes, somnolence (sleepiness) and dizziness are listed as very common side effects in the product information. Official safety information notes that these effects may impair abilities needed for tasks like driving or operating machinery.

---

Q: Is it safe long-term?

Official product information includes clinical trial data that assessed the medication's use over periods up to several months for its approved indications. This includes studies supporting use in conditions like neuropathic pain, partial-onset seizures, and fibromyalgia.

---

Q: What happens if I stop taking it suddenly?

Official information warns that if Sustac needs to be stopped, the dosage should be gradually reduced. Stopping the medication abruptly can lead to potential withdrawal symptoms, including insomnia, nausea, headache, anxiety, and excessive sweating. For patients taking it for seizures, abrupt discontinuation may also increase the risk of seizure frequency.

---

Q: What are the common drug interactions?

According to the product labeling, a key interaction involves medicines that also slow down the central nervous system. This includes substances like opioids and benzodiazepines, where co-administration may increase the occurrence of side effects such as dizziness, sleepiness, and respiratory concerns. It may also interact with some antidiabetic medications.

---

Q: Is it safe to take while pregnant?

Official information indicates that there are no adequate studies of Sustac in pregnant women. Animal studies have shown the potential for fetal structural abnormalities and other risks to development. The official information notes that a healthcare provider should assess the potential risk to the fetus against the potential benefits.

How to Store and Dispose of Sustac

The storage and disposal of Sustac (Nitroglycerin extended-release) must adhere strictly to the conditions mandated by official regulatory labeling to preserve drug potency and ensure safety.

---

Required Storage Conditions

Detail	Regulatory Requirement
Temperature	Store at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F).
Protection	Must be Protected from moisture and light.
Container	Keep in the original, tightly closed container.

---

Child-Safety and Disposal

Sustac must be stored out of the sight and reach of children. For disposal of unused or expired tablets, utilize a drug take-back program. If a program is unavailable, follow the specific governmental guidance for household disposal, which involves mixing the drug with an undesirable substance and sealing it before placing it in the trash. The medication must not be flushed down the toilet.